Longitudinal outcomes of different asthma phenotypes in primary care, an observational study by Khusial, R.J. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2018-04-11 and may be subject to
change.
ARTICLE OPEN
Longitudinal outcomes of different asthma phenotypes in
primary care, an observational study
Rishi J. Khusial1, Jacob K. Sont1, Rik J. B. Loijmans2, Jiska B. Snoeck-Stroband1, Pim J. J. Assendelft3, Tjard R. J. Schermer3 and
Persijn J. Honkoop1 for the ACCURATE Study Group
While asthma presentation is heterogeneous, current asthma management guidelines in primary care are quite homogeneous. In
this study we aim to cluster patients together into different phenotypes, that may aid the general practitioner in individualised
asthma management. We analysed data from the ACCURATE trial, containing 611 adult asthmatics, 18–50 year-old, treated in
primary care, with one year follow-up. Variables obtained at baseline (n = 14), were assessed by cluster analysis. Subsequently,
established phenotypes were assessed separately on important asthma outcomes after one year follow-up: asthma control (Asthma
Control Questionnaire (ACQ)), quality of life (Asthma Quality of Life Questionnaire (AQLQ)), exacerbation-rate and medication-
usage. Five distinct phenotypes were identiﬁed. The ﬁrst phenotype was predominantly deﬁned by their early onset atopic form of
asthma. The second phenotype mainly consisted of female patients with a late onset asthma. The third phenotype were patients
with high reversibility rates after bronchodilator usage. The fourth phenotype were smokers and the ﬁnal phenotype were frequent
exacerbators. The exacerbators phenotype had the worst outcomes for asthma control and quality of life and experienced the
highest exacerbation-rate, despite using the most medication. The early onset phenotype patients were relatively well controlled
and their medication dosage was low.
npj Primary Care Respiratory Medicine  (2017) 27:55 ; doi:10.1038/s41533-017-0057-3
INTRODUCTION
Over 300 million people suffer from asthma globally, which makes
it one of the most common chronic diseases in the world.1
International guidelines such as the Global Initiative for Asthma
formulate the long-term goals of asthma treatment as the
accomplishment of asthma control and reducing the exacerbation
rate.2,3 Although people with asthma generally perceive their
asthma control positively, the level of actual clinical asthma
control in Europe fails to reach these goals.4–7 Part of the reason
these goals are not met, is that asthma is a heterogeneous disease,
while management and treatment according to current guidelines
is, despite its step-wise approach, more of a one-size-ﬁts-all
approach, that is not personalised according to individual patient
characteristics. Tailored interventions using FeNO8 or sputum
eosinophils9, for example have proven successful in reducing
steroid dose and exacerbation rate, respectively.
Currently, several different asthma phenotypes that cluster
speciﬁc patient characteristics have been described.10–13 Mana-
ging asthma patients according to these phenotypes might be an
approach that allows for individualising treatment. Thus far most
of the studies identifying phenotypes have been performed in
hospital care. However, in many countries, the majority of the
individuals with asthma are treated in a primary care setting.14–16
Therefore, it is important to assess whether these phenotypes are
similar in primary care. Additionally, the majority of the current
hospital care-based phenotypes require certain measurements not
easily available in primary care. This hampers implementation and
it would be preferable if primary care phenotypes consist of
measurements easily obtainable to the general practitioner (GP) or
practice nurse (PN). Therefore, as the ﬁrst part of our study we
aimed to cluster primary care asthma patients into distinct
phenotypes based on easily obtainable patient characteristics
using a clustering strategy.
Furthermore, continuing onward with these phenotypes,
efﬁciency of asthma management might be improved if it is
known which phenotypes require more frequent assessments by a
GP or PN, because they present a greater risk of future adverse
outcomes and which phenotypes could be safely assessed less
frequently due to more favourable long-term asthma outcomes.
Therefore, in the second part of our study we determined the
long-term differences in important asthma outcomes between
different phenotypes. We aimed to assess differences in our
established phenotypes in terms of asthma control, quality of life,
medication usage and exacerbation frequency, after a 12-month
follow-up period.
RESULTS
The results described here were generated in a ﬁve step process,
which is described in detail in our methods section. In the ﬁrst
step we assessed potential variables to be included in our cluster
analysis and these are listed in Table 1. Overall, our population is
comparable to the general asthma population in primary care in
Europe, including a higher percentage of females (Table 1).3,17
Next, we performed a factor analysis which showed four distinct
factors. These factors were deﬁned by: (1) the level of self-reported
patient health, labelled ‘functioning’; (2) the combination of
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prescribed medication, labelled ‘medication’; (3) the atopic status,
labelled ‘allergy’ and (4) the socioeconomic status, labelled ‘SES’.
The results of the factor analysis are reported in Table 2, results are
standardised z-scores and positive scores represent an above
average result (see methods). Subsequently in step 3 data
transformation was performed for selected variables. FEV1 was
adjusted for gender and missing variables were imputed. Then we
performed a cluster analysis with 14 variables (including factors),
all variables were continuous except gender.
An agglomerative hierarchical cluster analysis with baseline
data showed that the optimal amount of clusters was ﬁve. A
general overview of the clusters is presented in Table 2. In
summary, the ﬁrst phenotype consisted of patients with an early
diagnosis of asthma and a high prevalence of allergies. This
phenotype also reported the highest functioning scores and
socio–economic status (SES). Most patients in this phenotype were
male. For further reference, this phenotype was labelled ‘early
atopic’.
The second phenotype, labelled ‘late onset female’, was the
largest group. It consisted mainly of females and the mean age of
diagnosis was slightly higher than in the other phenotypes.
The third phenotype, labelled ‘reversible’, consisted of patients
with high reversibility after bronchodilation and the lowest
baseline FEV1 percentage predicted. This group also reported
the most symptoms in the Asthma Control Questionnaire (ACQ6).
The fourth phenotype, labelled ‘smokers’, included patients
with the highest amount of pack years smoked. This not
necessarily meant the patients were still active smokers during
the study (a total of 48% was actively smoking). This group also
reported the lowest SES.
The ﬁfth and last phenotype, labelled ‘exacerbators’, comprised
of patients who frequently experienced exacerbations in the year
previous to the study. They also reported relatively high ACQ
scores.
Long-term outcomes
Finally we analysed long-term outcomes of important asthma
parameters for each of the phenotypes.
ACQ. Figure 1a presents the results of the ACQ during 12-month
follow-up for each of the phenotypes. Data at baseline (month 0)
were used in the cluster analysis to determine the phenotypes.
The ‘reversible’ and the ‘exacerbators’ phenotypes had the most
symptoms at baseline, showed the most improvement during
follow-up, but at 12-month follow-up still reported most
symptoms. The ACQ score of the other clusters were relatively
stable over time and ﬂuctuated around the results of the baseline
measurement. The ‘late onset female’ and the ‘smoker’ pheno-
types had very similar overall results. The ‘early atopic’ phenotype
experienced a clinically meaningful lesser amount of symptoms
throughout the study (deﬁned as exceeding the minimal
important difference (MID) of 0.5), compared to the ‘reversible’
and ‘exacerbators’ phenotypes (ACQ-results respectively 0.63,
compared to 1.26 and 1.17).18
Table 1. Baseline data of total research population
Variable Total (n= 611)
Gender (% female)a 68.4
Age, yr (SD)a 39.4 (9.1)
Age of diagnose, yr (SD)a 20.8 (14.4)
Length, cm (SD) 172.4 (10.1)
Weight, kg (SD) 79.0 (17.7)




Active smokers (% patients) 14
Pack years smoked, yra 4.7
Exacerbations in past 12 months, no per patienta 0.67
FeNOa 23.3
FEV1 (% predicted)a 95
a Variable used in cluster analysis
b Percentage reversibility accomplished after use of a bronchodilator
Table 2. Clustering results
Variable Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5
(n= 170) (n= 236) (n= 62) (n= 62) (n= 81)
Early atopic Late onset female Reversible Smokers Exacerbators
Gender (%female) 45.3 85.2 75.8 51.6 75.3
Age, yr 34.8 42.5 34.5 44.5 39.7
Age of diagnose, yr 13.7 27.1 16.5 23.5 18.5
BMI, kg/m2 25.2 27.4 25.1 25.5 27.5
ACQ6 0.5 0.9 1.7 1.0 1.6
AQLQ 6.3 5.6 5.3 5.8 5.1
Reversibility, % −1.8 2.7 35.1 10.7 10.9
Pack years smoked, yr 1.2 2.9 2.1 24.0 4.4
Exacerbations in past 12 months, no per patient 0.1 0.4 0.5 0.4 3.0
FEV1 (% predicted) 96 100 70 89 99
Factorsa
SES 0.20 0.01 −0.16 −0.48 0.03
Allergy 0.27 −0.20 0.05 −0.33 0.22
Functioning 0.42 −0.18 −0.16 0.15 −0.37
Medication −0.38 0.18 0.05 0.01 0.24
a Factor scores are standardised Z-scores with mean = 0 and standard deviation = 1
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Asthma quality of life questionnaire (AQLQ). Over the 12-month
follow-up, all phenotypes gradually improve in quality of life over
time, with the ‘exacerbators’ phenotype showing the most
improvement. After 12-month follow-up the ‘early atopic’
phenotype has the best asthma related quality of life (AQLQ =
6.35). This was >0.5 points above both the ‘reversible’ (5.53) and
the ‘exacerbators’ (5.49) phenotype, again indicating a clinically
meaningful MID for the AQLQ.19 The AQLQ-results of the different
phenotypes never cross each other.
Exacerbations. In Fig. 2 the cumulative mean amount of
exacerbations during the study is presented. The ‘exacerbators’
phenotype experienced the highest absolute amount of exacer-
bations in the follow-up period. The ‘smoker’ phenotype also had
a relative high amount of exacerbations compared to the other
phenotypes.
Medication usage. Figure 3a shows the total dosage of inhaled
corticosteroid (ICS) after 12-month follow-up for each of the
phenotypes and Fig. 3b shows the change during the study in
guideline derived treatment steps.2 The ‘exacerbators’ phenotype
were prescribed the highest ICS dosage after 12 months and also
increased their dosage the most during the study. The ‘early




In this study we established ﬁve distinct asthma phenotypes in
primary care. Important long-term asthma outcomes, such as
asthma control, quality of life, exacerbation rate and medication
usage differed between these phenotypes after 12-month follow-
up. Therefore, taking into account asthma phenotypes allows for a
more personalised treatment approach and in so doing can have
important consequences for long-term asthma outcomes.
Interpretation of ﬁndings in relation to previously published work
In our study in primary care we established ﬁve distinct asthma
phenotypes. Previously, Haldar et al.11 found three clusters in a
primary care population, namely: ‘early-onset atopic asthma’,
‘obese noneosinophilic’ and ‘benign asthma’. In our study the
‘early-onset atopic’ phenotype had the most favourable outcomes,
in terms of asthma control, quality of life and exacerbations, while
using the lowest dosage of medication. This is in contrast to
previous studies that suggest that early onset atopic patients use
higher ICS dosage than other phenotypes.20 This can be attributed
to our additional speciﬁc ‘exacerbators’ phenotype, which can be
seen as the subset of patients with the worst long-term asthma
outcomes. Therefore, by using our phenotypes, patients with the
worst long-term outcomes are separated from the other
phenotypes and consequently treatment can be more targeted
to those with an increased risk.
The clusters in the study by Ortega21 showed, despite the high
average body mass index (BMI), some familiarities with our
clusters. Cluster 3 has relative many allergic patients but since this
is not the group with the youngest patients, this does not directly
corresponds with our ‘early onset atopic’ phenotype. Cluster 7
could correspond with our ‘exacerbators’ phenotype and cluster 5
could correspond with our ‘smokers’ phenotype. However,
acknowledging the differences in variables used, the clusters are
not directly the same.
An important reason that we found several different pheno-
types from previous studies was that we added variables easily
assessed in primary care. We also included FeNO as a variable in
our analyses as it is now available in primary care and is shown to
be cost-effective.22 We also included the variable pack years
smoked in the cluster analysis. The amount of pack years smoked
highly inﬂuences respiratory disease progression. This is
Fig. 1 a. ACQ score in a 12-month study period divided per cluster. Time period 0 is the baseline measurement. A high ACQ scores stands for
less controlled asthma. ACQ-scores can be divided in: controlled (ACQ score≤ 0.75, below green dotted line), partly controlled (0.75< ACQ
score< 1.5), or uncontrolled (ACQ score≥ 1.5, above red dotted line). The clusters started out with different baseline scores. The ‘exacerbators’
and ‘reversible’ phenotypes started as uncontrolled, but after 12 months progressed to partly controlled. The ‘smokers’ and ‘late onset female’
managed as partly controlled.33 The only group with controlled asthma is the early atopic group. b. AQLQ scores in a 12-month study period
divided per cluster. Time period 0 is the baseline measurement. Higher AQLQ scores mean a better quality of life. The ‘late onset female’ and
the ‘smokers’ have comparable starting and ending values, and a small progress can be noted for both groups. The reversible and
exacerbation phenotypes have the highest increase in quality of life in the 12-month study period, albeit still lower than the other
phenotypes. In all groups a decrease in scores can be noted if month 12 is compared to month 9
Fig. 2 Cumulative amount of exacerbations in a 12-month study
period divided by cluster. At 3-month interval, the total amount of
exacerbations experienced were added in a cumulative score for
every phenotype. The trend of the exacerbation progression over
time is close to linear
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somewhat reﬂected in the ‘smokers’ phenotype with a higher
exacerbation rate. In contrast to previous studies, we did not
detect one speciﬁc cluster of obese patients.11,20 One possible
explanation could be the relatively high mean BMI (26.4) in our
population, which allows for less distinction purely based on
weight. This high mean BMI is comparable with the average BMI in
western society.23–25
Strengths and limitations
An important strength of our study is that we speciﬁcally studied
an asthma population managed in primary care, while most
former studies assessed phenotypes in hospital care. In our study
we included many patients (n = 611) and we had 12-month
follow-up data. We speciﬁcally used variables that were easily
measurable and did not look at eosinophilic airway inﬂammation
and comparable laboratory-requiring variables.
Another strength of our study is the heterogeneous group of
primary care patients, of which many different variables were
collected during the original trial, which allowed us to use many
variables for clustering. The variable selection and analyses were
based on results from previous literature.
A limitation of our study was that the differences within a
phenotype (from baseline to 12 months) were usually higher than
differences between phenotypes (at a certain point). While the
‘exacerbators’ phenotype had the relative highest risk of devel-
oping an exacerbation in the future, the absolute amount of
exacerbations they experienced declined in the study year (mean
0.85 exacerbations per patient per year (exac/pt/yr)), compared to
the year prior to the study (3.0 exac/pt/yr). This can partly be
attributed to the beneﬁcial effect of participating in a clinical trial,
since the total amount of exacerbations in the whole research
population also decreased (0.67 to 0.24 exac/pt/yr).
Another limitation of our study was the amount of patients per
phenotype. Even though our general asthma population com-
prised of many patients, some phenotypes were too small
(smallest phenotype n = 62) to perform further analysis, which
resulted in our study having a more descriptive character. Further
studies require more patients per phenotype to perform optimal
treatment strategy analyses.
In our study we used the data set from the ACCURATE trial, in
which patients were randomised into three different treatment
strategies (‘partially controlled’, ‘controlled’ and ‘FeNO’).22,26 Our
phenotypes were determined using baseline data from this trial,
which were obtained before randomisation. Therefore the
treatment strategies of the original trial had no inﬂuence on the
establishment of the phenotypes. However, long-term outcomes
could have been inﬂuenced if one of the treatment strategies of
the original trial would have been overrepresented in one of our
phenotypes. Therefore we performed a sub-analysis and this
showed that treatment strategies were roughly equally distributed
amongst the phenotypes (data not shown).
Implications
Determining different phenotypes is of aid in identifying patients
at risk, enabling primary care physicians to guide management,
including frequency of control visits, treatment decisions and
proper allocation of patients to primary care or hospital care
management. To date, to describe people with asthma, usually
mean scores are used, while the spread of scores is high. This
makes it hard to make general statements about asthma patients
in primary care and agglomerating all these different patients
together leads to ineffective use of the healthcare system.
Differentiating by using phenotypes might tackle this problem
and the differences in long-term outcomes between the
phenotypes in our study show that they function differently from
one another, which underscores the beneﬁt of phenotyping
asthma patients in primary care.
For example, the ‘exacerbators’ phenotype clearly has the least
favourable outcomes, even though they are prescribed the
highest level of medication. Therefore, only increasing medication
dosage for these patients is insufﬁcient. Even though exacerbation
rate improved in comparison to the year before the study, it is still
high, while patients might experience additional side-effects. This
suggests these patients additionally require a more thorough
review of other (non-pharmacological) treatment options and if no
clear improvements can be made, they should probably be
referred to specialised care.26 On the other side of the spectrum is
the early onset atopic phenotype. This group had good results on
both ACQ and AQLQ and they had the lowest medication level.
Patients with this phenotype show stable and favourable long-
term outcomes and they are potentially suited to a more ‘as
necessary’ approach to asthma management, for example by
using online self-management through eHealth, alongside ‘as
necessary’ contact with a healthcare provider.27 Similarly, the 'late
onset female' phenotype, also shows more favourable outcomes.
Together these two phenotypes comprise 66% of the total study
population. It would be beneﬁcial for both patients and the
Fig. 3 a Medication dosage at 12 months. All inhalation corticosteroid medication usage has been converted to beclomethasone equivalent.
The ‘exacerbators’ phenotype had the highest dosage beclomethasone (794 µg) and the ‘early atopic’ group had the lowest dose (496 µg). The
reversible group had an average dose of 628 µg. b Medication entry–exit level. This ﬁgure shows the mean guideline derived medication
usage for each phenotype, with steps from 0 (no medication) to 5 (daily oral prednisolone).26 Over time it can be noted that while most
phenotypes stayed roughly in the same medication step, the mean increase in medication usage for the ‘exacerbators’ phenotype was nearly
one step. Phenotype ‘reversible’ also had a considerate increase in medication usage (from 2.0 to 2.4)
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healthcare system as a whole if visits to the GP-ofﬁce for these
phenotypes could be limited.
Further research should focus on the implementation of
phenotype usage in primary care. Firstly it must be assessed
how to easily deﬁne a particular patients’ phenotype within
current asthma management and how often this should be
repeated in order to continually improve long-term asthma
outcomes.13 Also, while we did show long-term outcomes are
different for phenotypes, it is currently not certain that changing
therapy according to this knowledge will actually lead to
improved outcomes. Although this seems likely, a future
prospective study is needed, which could also assess the
consequences of implementing phenotypes in general practices,
since if it is time-consuming while real life impact on long-term
outcomes are negligible, use of phenotypes is questionable.
CONCLUSIONS
Clustering of primary care asthma patients resulted in ﬁve distinct
phenotypes. These phenotypes differ in long-term outcomes, as
measured by ACQ, AQLQ, exacerbation frequency and medication
usage. Using these phenotypes in asthma treatment may result in




For this study we used data collected in the Asthma Control Cost-Utility
Randomised Trial (ACCURATE), a multicentre randomised trial performed in
the Netherlands. The goal of this original study was to assess three
different treatment strategies of asthma.22,28 The results of this trial have
previously been published. For a detailed description of study procedures
and participants see the published protocol.
In short, participants were selected in primary care ofﬁces in both rural
and urban areas in the Netherlands. All patients gave informed consent.
Inclusion criteria were a doctors diagnosis of asthma, age 18–50 year-old,
and a prescription for inhalation corticosteroid’s (ICS’s) for at least 3 months
in the previous year. Patients were excluded if they had used an oral
corticosteroid in the month prior to the study, were unable to speak Dutch
or suffered from severe comorbidity. Methods were performed in
accordance with relevant regulations/guidelines. The trial was approved
by the Medical Ethics Committee of Leiden University Medical Center and
registered at http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1756.
Study design
The ACCURATE study was a cluster randomised trial with a follow-up of
12 months. For the establishment of the phenotypes baseline data were
used, which contained data of patients before randomisation altered
outcomes. Participants were reviewed every 3 months and if necessary
treatment was adjusted. Additionally patients ﬁlled out online question-
naires. For our study we retrospectively analysed the data. Long-term
outcomes of phenotypes were assessed using the data from the three
monthly assessments and online questionnaires.
This analysis in this study consisted of the following ﬁve steps:
1. Identiﬁcation of potentially relevant variables
2. Factor analysis
3. Data transformation, if necessary
4. Cluster analysis
5. Comparison of long-term outcomes
In the ﬁrst step all potentially relevant variables were identiﬁed based on
previous studies and relevant guidelines.2,11,29 General patient character-
istics (gender, age, BMI, income and education level) and asthma speciﬁc
variables were selected. All variables used for the analysis are listed in
Table 1. To determine the different phenotypes, baseline data were used to
approximate real life circumstances.
In the second step, we performed a factor analysis. A factor analysis was
conducted before clustering to combine interrelated variables that
measure the same construct, namely: SES, allergy, functioning scores on
the sf36 questionnaire and medication. A varimax rotation was used to
maximise variance.30
In the third step, part of the data was transformed to increase validity of
the analysis and FEV1 was adjusted for gender and extreme outliers. Data
were imputed if there were missing values at random, with STATA-
command imputation. Additionally all variables used for clustering were
standardised, with a mean of 0 and a standard deviation of ±1 in order to
give all variables equal weight in the cluster analysis.
The fourth step consisted of a Wards linkage cluster analysis.31 This is the
most optimal agglomerative hierarchical clustering strategy for the given
data. Following Ward’s criterion for minimum variance the within-cluster
variance will be as small as possible for the most similar clusters. The distance
between the clusters was measured with the squared Euclidean distance.
The ﬁnal step of the analysis was to assess long-term outcomes for every
individual phenotype.
The ACQ6, the AQLQ at 12 month-follow-up, the amount of severe
exacerbations during the study-period and medication prescription were
selected as long-term outcomes. The ACQ6 is a six-question questionnaire
aimed to map asthma control, it scores between 0–6 and higher scores
represent worse asthma control.18 The AQLQ assesses asthma related
quality of life, the score has a range from 0 to 7 with higher scores
representing a higher quality of life. A severe asthma exacerbation was
deﬁned as a course of oral prednisolone prescribed for worsening asthma
for three or more days, or an emergency department visit/hospitalisation
due to asthma.18
Medication prescription was deﬁned as the total usage of ICSs,
recalculated to beclomethasone equivalent dosage. Additionally the use
of long-acting beta agonists was presented separately. Finally all
medication usage was also classiﬁed into one ‘medication step’, based
on the steps presented in the NAEPP guidelines.32
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